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INTRODUCTION: 
Cardiovascular disorders are a major cause of mortality and morbidity not only among 
industrialized and developed nations but are also emerging as a major contributory factor to 
overall morbidity and mortality in developing countries like Malaysia. According to 
Malaysia's book of health records (Ministry of health, 1999) the rate of death due to 
cardiovascular events is 20.33% and cerebrovascular events constituting 7. 74% of the total. 
Various factors contributing to these cardiovascular events include _aging, obesity, smoking, 
hyperlipidemias, hypertension and diabetes mellitus. In many instances of cardiovascular 
events occurring as a result of the aforementioned factors, tbrombogenesis is an important 
single most common underlying pathological process. While females are generally protected 
from cardiovascular diseases before menopause, this population is at a higher risk of such 
events compared. to their male counter parts due to the loss of protection by estrogen after 
menopause (Wenger et. al. 1993 ). Coronary artery disease is then a major cause of death in 
postmenopausal women as it is more age dependent in women than in men. A big proportion 
of all cardiovascular events in either sex are thrombotic in nature. Therefore it is essential to 
critically understand the structure and functio~ of not only the constituents of blood but also 
various events stimulating such tbrombogenes1s. 
Platelet activation either disturbed and I or increased plays a major role in the 
pathophysiology of thrombosis. In many instances of cardiovascular events, tbrombogenesis 
is an important single most common underlying pathological process. Different techniques 
show changes in platelet reactivity but cannot establish its association with the particular 
condition. Diagnostic value of flow-cytometric analysis of platelets activation in thrombotic 
events is being established. At the same time whole blood flow-.cytometry has none of the 
limitations, which are encountered by other techniques of platelet activation analysis. With 
~ platelet~ivation-there-is-conformation-changes--in\JP structure resUlting m neo-epttopes 
while at the same time some new surface receptors are secreted. These neo-epitope-8- can be 
targeted by monoclonal antibodies. 
Whole blood flowcytometry in the absence of an added exogenous platelet agonist 
determines the activation state of circulating platelets. In addition to this inclusion of 
exogenous agonist in the assay enables analysis of the reactivity of the circulating platelets in 
vitro. In our study we did not perform the later part to see the rea~tivity of the circulating 
platelet. . 
Pre-menopausal women have lower risk of cardiovascular disease compared to post-
menopausal women, which is more age dependent in women than in men. This might be due 
to the loss of protection by estrogen after menopause (Wenger et. at. 1993). The association 
of platelet activation and cardiovascular thrombotic events is well established. Therefore it is 
essential to critically understand the structure and function of not only the constituentS of 
blood but also various events stimulating such thrombogenesis. 
OBJECTIVES: 
(i) Primary objectives. 
1 To develop and optimize method for in vivo determination of platelet activation 
markers by flow cytometer. 
2 To detennine platelet activation markers by the developed technique in pre and 
postmenopausal women. 
(ii) Secondary objectives. 
1 To establish a relationship between platelet activation markers serum cholesterol, 
B1v.11, age in both groups and also estradiol levels in post menopausal wdmen. 
MATERIALS & METHODS: 
Materials 
CaHbrite™Beads · 
Becton Deckinson CaliBRITE beads are designed for use with F ACS® family of flow 
cytometers. The beads are used to adjust instrument settings, set fluorescence compensation, 
and check instrument sensitivity. For om study we use calibration beads with every run of 
samples for monitoring instrument perfonnance. 
Three-color kit was used in this study. It contains fluorescein isothiocyanate (FITC)-
labeled bead, a phycoerythrin (PE)-labeled beads, a peridinin chlorophyll protein (PerCP)-
Iabeled bead, and unlabeled beads. The following list illustrates PMT.light signal detection: 
1. Fluorescence-1 (FL 1) FITC (yellow-green) 
2. Fluorescence-2 (FL2) PE (red-orange) 
3. Fluorescence·3 (FL3) PerCP (red) 
4. Fluorescence-4 (FL4) APC (red) 
Each fluorochrome emits light over a range of wavelengths when excited by the laser bean. 
Thus, a portion of the FITC signal is detected by the FL2 PMT, a portion of the PE signal is 
detected by the FLl and FL3 PMTs; a portion of the PerCP signal is detected by the FL4 
PMT (PerCP signal is not detected by the FL2 PMT); and a portion of the APC signal is 
detected by ·the FL# PMT. This "spectral overlap'~ must be corrected using electronic 
-compensation. ealiBRITE"beads are usea to determine tlie appropnate compensation ~settings . 
. -
After the instrument settings have been determined, CaliBRITE beads are used to 
evaluate instrument sensitivity. Forward scatter (FSC) and side scatter (SSC) instrument 
sensitivity are measured by the mean channel separation between the light-scatter signal of 
the beads and background signal (electronic and optical). FLl, FL2, and FL3 fluorescence 
sensitivity is detennined by measuring the mean channel separation ~etween the signal of the 
labeled beads and the unlabeled beads. A minimum channel separation must be met for the 
scatter and fluorescence parameters. This allows cells to be distinguished from sample debris 
or background signal and for dimly stained cells to be distinguished from unstained cells 
(Becton Dickson CaliBRITETm beads package insert, 1998). 
Preparation of Test.S~spension 
Suspensions were prepared in two tubes (Falcon disposable 12X~5 mm capped 
polystyrene test tubes, BD catalogue number 2058) immediately prior to use. Beads vials 
were used after gentle mixing. Tubes were labeled as unlabeled and labeled. In unlabeled 
tube 1ml of sheath fluid added and then one drop of unlabeled beads were added .In the 
second tube (labeled) 3ml of sheath fluid was added with one drop each of unlabeled, FITC, 
PE, and PerCP beads. PMf voltage was adjusted using unlabeled tube while labeled tube was 
used for fluorescence compensation, and sensitivity test. Manual optimization was done 
before running the cells. 
MONOCLONAL ANTIBODIES USED 
LCD61 
CD61 recognizes an 11 0-kdalton (kDa) protein, also known as gplla, the common f3-
subunit (integrin (33-chain) of the gpllblllla complex and the vitronectin receptor (VNR) (von 
dem Borne et. al. 1989 & Modderman, 1989). The gpllblllla complex and the VNR are 
integrins, ie, a/(3-heterodimeric glycoprotein complexes that are .involved in cell adhesion 
(Springer, 1990, Hynes, 1992 & Parmentier, 1990). With the CD41 antigen (gpiib or allb), 
CD61 antigen forms the gpllb!ITia complex, which acts as a receptor for fibrinogen, von 
Willebrand factor (vWf), fibronectin, and vitronectin on activated platelets (Fijnheer et. al. 
1990). With CD51 antigen, the CD61 antigen forms the VNR, which mediates activation-
independent cell adhesion to vitronectin, vWf, fibrinogen, and thrombospondin. 
The CD61 antigen is found on all normal resting and activated platelets (Modderman, 
1989). This is further supported by the individuals with Glanzmann's thromboasthenia which 
have >90% reduction of binding of CD61, and heterozygote carriers of the disorder show 
approximately 50% reduction (Jennings et.al., 1986). The Cb61 antigen is also found on 
endothelial cells, megakaryocytes, and on some myeloid, erythroid, and T -lmphoid leukemic 
cell lines (von dem Borne et. al. 1989 & Modderm.an, 1989). CD61 is used in following 
research applications 
Platelet and platelet-derived microparticles in blood 
Megakaryocytes and megakaryocytic leukemias 
Idiopathic thrombocytopenia in blood and tissue. 
Cell adhesion. 
H. PAC-1 
PAC-1 recognizes an epitope on the glycoprotein llblllla (gpllb/Illa,a.ITb.p3) complex 
of activated platelets at or near the platelet fibrinogen receptor (Shattil et.al., 1985, Abrams 
-et.al..,-1-990-&-Shattil-et-;-&l-;;-l98-7}.-'Fhe--gpllb/Hia-complex-is-Iocated-on-tlle--surfac-e-
membrane of resting platelets (Abrans & Shattil, 1991 ). Platelet activation induces a calcium ... 
dependent conformational change in gpllblllla that exposes a ligand binding site (Ginsberg 
et. at., 1990 & Sbattil et al., 1993). Four adhesive macromolecules are capable of interacting 
with the activated form of gpllb/IIIa: fibrinogen, vWf, fibronectin, and vitronectin (Bennet 
et.al., 1988). PAC-I binds only to activated platelets and appears to be specific for this 
recognition site within gpllb!IIIa (Michelson, 1996a, Taub et. al., _.1989 & Abrams et. at., 
1992). Approximately 45,000 to 50,000 gp lib/Ilia receptors appear on the pl~telet surface 
upon activation. (Shattil, 1985 & Abra~s, 1991 ). The. bi~d~ng of. fibrinogen to gpllb/Illa 
receptor is requtred for platelet aggregation and PAC .. I inhibtts fibrtnogen mediated platelet 
aggregation. PAC-t is a pentam~ric IgM K-i~munogl~bulin. Activation-dependent antibody 
binding can be affected by fixation and chotce of anticoagulant. P AC-1 will not bind fixed 
platelets or EDT A-treated blood. 
I". 
m.CD62P 
The CD62P antigen, also known as platelet activation-dependent granule-external 
membrane (PADGEM) protein or granule membrane· protein (GMP-140), is a 140-kdalton 
single-chain polypeptide (Larsen et. al., 1989). The CD62P antigen is a member of the 
selectin family of adhesion molecules and mediates the adhesion of activated platelets to 
neutrophils and monocytes in hemostasis (Larsen et.al., 1989, Hamburger & McEver, 1990 
& Pannentier et.al., 1990). 
The CD62P antigen is an integral membrane protein associated with a-granules of 
platelets, Weibel-Palade bodies of endothelial cells, and megak:aryocytes. It is expressed on 
the internal a-granule membrane of resting platelets. Upon platelet activation and granule 
secretion, the a-granules membrane fuses with the external plasma membrane and the CD62P 
antigen is expressed on the surface of the activated platelets (Larsen et. al., 1989, Stenberg et. 
al., 1985, Hamburger & McEver, 1990, Metzelaar et. al., 1990 & Bonfanti et. al., 1989). 
CD62P antibody is composed of IgG1 heavy chains and kappa light chains. It is being used 
in identification of in vivo-activated platelets, studies of platelet aggregation and also for in 
vitro platelet activation. 
Analysis and Data acquisition 
Logarithmic amplification for forward scatter (FSC) and side scatter (SSC) was 
selected. CD 61 PerCP positive events were acquired. Platelets stained with isotype control 
were used to adjust FLl and FL2 voltage so that FL1/FL2 baseline signals are depicted 
squarely in the frrst decade in FLl vs FL2 dot plot. Platelets stained with CD 62 PerCP and 
activation dependent monoclonal antibodies were used to adjust compensation. Ten thousand 
activation independent platelet events were acquired for each sample. Total platelet 
population was displayed as two color dot plots and the results were used for statistical 
analysis. For PAC-I positive events cell percentage present in quadrant 2 and 4 were added. 
Similarly for CD 62P positive events quadrant 3 and 4 were added. Events, which were 
present in quadrant 4, were those platelets, which were positive for both PAC-1 and CD 62P. 
CV of both activation dependent antibodies was calculated with standard formula and 
it was 5.22 and 3.8% for both CD62P and PAC-1 respectively. After standardizing the 
technique, we evaluated platelet activation markers in 49 post .. menopausal (56.16 ± 0.083 
years; mean± SEM) and 42 pre-menopausal women (39.38 ± 1.09). Informed verbal consent 
was taken before recruiting subjects. Already standardized technique was used for in vivo 
evaluation of platelet activation markers by flow .cytometer using 3 ... color analysis (CD61 
PerCP, CD 62P & PAC-1). Care was taken during blood sampling and processing to 
..,minimize-in-Vitro-aGtivation-of-platelets~.-----------------------
RESULTS: 
The aim of the study one was to optimize the rnethod for detection of platelet 
activation markers by flow cytometer. Accuracy and precision of the technique was frrst 
detenn.ined. Blood samples from 21 subjects were divided into two and stained and ran 
separately for the detennina~ion of CD 62P and PAC-I. Means and standard deviations of 
readings were calculated whtch were used to calculate the co-efficient of variation. The co-
efficient of variation for both CD 62P and PAC-1 were 5.2 and 3.8% respectively. The mean 
values and CV calculated for both CD 62P and PAC-I respectively. 
To achieve our secondaty objectives, a total of 91 women, 49 post and 42 pre-
menopausal recruited Clinical characteristics and variable of interests of volunteers are given 
in tables. 
Calculation of standard deviation and coefficient of variation of CD62P 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
Total 
Mean 
Observation 1 Observation 2 
(x) (y) 
1.00 1.04 
0.25 0.28 
0.49 0.40 
0.55 0.58 
0.85 0.75 
0.12 0.15 
0.55 0.49 
0.37 0.32 
0.33 0.37 
0.04 0.06 
0.36 0.28 
0.33 0.34 
4.53 4.66 
3.25 3.33 
0.74 0.69 
0.35 0.25 
0.19 0.23 
0.57 0.61 
1.35 1.24 
1.22 1.19 
1.05 1.09 
18.49 
0.8804 
SD = "'1/2n I: (x-y)1 
= "1/2 X 21 (0.0906) 
·= "0.0021 
SD =0.046 
CV =SD/MeanX 100 
= 0.046/0.8804 X 100 
CV =5.22 o/o 
(x-y) (x~)! 
-0.04 0.0016 
-0.03 0.0009 
0.09 0.0081 
-0.03 0.0009 
0.10 0.01 
-0.03 0.0009 
0.06 0.0036 
0.05 0.0025 
-0.04 0.0016 
-0.02 0.0004 
0.08 0.0064 
-0.01 0.0001 
.. 0.13 0.0169 
-0.08 0.0064 
0.05 0.0025 
0.10 0.01 
-0.04 0.0016 
-0.04 0.0016 
-0.11 0.0121 
0.03 0.0009 
-0.04 0.0016 
1.2 0.0906 
0.057 
Calculation of standard deviation and coefficient of variation of PAC 1 
No 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
Total 
Mean 
Observation 1 Observation 2 
(x) (y) 
4.69 5.22 
5.52 5.28 
2.77 2.67 
5.77 5.21 
4.19 4.09 
1.59 1.70 
4.40 4.22 
1.35 1.51 
1.51 1.55 
0.89 0.74 
0.74 0.75 
-
1.47 1.50 
19.12 19.51 
9.19 . 9.74 
4.38 4.46 
1.43 1.32 
1.11 1.01 
3.81 3.84 
18.42 18.51 
11.69 11.87 
12.18 11.36 
116.22 
5.534 
SD = ~1/ln L (x-y)2 
= ""1/2 X 21 (1.944) 
= ~0.046 
SD =0.215 
CV = SD I Mean X 100 
= 0.215·/5.534 X 100 
-----,€V-=--3.8°A 
{x-y) 
-0.53 
0.24 
0.1 
0.56 
0.1 
-0.11 
0.18 
-0.16 
-0.04 
0.05 
-0.01 
-0.03 
-0.39 
-0.55 
-0.08 
0.11 
0.1 
-0.03 
-0.09 
-0.18 
0.82 
4.46 
0.212 
Clinical characteristics of Pre-menopausal women 
VARIABLE MINIMUM MAXIMUM MEDIAN 
" 
AGE 22 51 40.00 
BMI 15.61 35.10 23.95 
CHOLESTEROL 3.65 7.06 5.53 
(x-y):z 
0.2809 
0.0576 
0.01 
0.3136 
0.01 
0.0121 
0.0324 
0.0256 
0.0016 
0.0025 
0.0001 
0.0009 
0.1521 
0.3025 
0.0064 
0.0121 
0.01 
0.0009 
0.0081 
0.0324 
0.6724. 
1.944 
STANDARD 
DEVIATION 
7~07 
4.21 
0.85 
Clinical characteristics of Post-menopausal women 
VARIABLE 1\fiNIMUM MAXIMUM MEDIAN STANDARD 
DEVIATION 
AGE 47 65 55.00 5.79 
BMI 16.70 35.10 25.80 4.37 
CHOLESTEROL 4.45 10.04 6.10 1.26 
ESTRADIOL 18.40 66.60 35.46 11.58 
(Age in years; BMI in kg I meter square; Cholesterol (l'otal cholesterol) in mmo/IL,· Estradiol 
levels in pmo/IL) 
To compare different parameters between the two groups one way ANOVA was 
done. Age and total cholesterol was significantly different between the two groups while it 
was not the case with B:MI which was not significantly different between the two groups. 
Results from study 2 showed that platelet activation markers CD62P and PAC1 were 
significantly low in Premenopausal groups as compared to post menopausal group. In post 
menopausal women CD62P was 7.2855± 1.6354 vs. 0.8887 ± 1.922 (mean± SEM, p < 
0.001) of the pre-me.nopausal women. PAC-I in post menopausal women was significantly 
higher (29.4448 ± 3.0456, p = 0.001) as compared to pre-menopausal women (5.2201 ± 
0.7101, p = 0.000). 
One of the secondary objectives of the study was to correlate platelet activation 
markers with age, cholesterol and B1vtl in both the groups and also to correlate estradiol level 
with activation markers in post-menopausal group of volunteers. 
Comparison of clinical characteristics of botb pre- and post- menopausal women. 
VARIABLE PRE- POST- p value 
MENOPAUSAL MENOPAUSAL 
AGE 39.38±1.09 56.16±0.83 0.000 
BMI 25.09±0.64 2535±0.62 0.775 
CHOLESTEROL 5.53±0.13 6.41±0.18 0.000 
(Age in years; BlVJI in kg I meter square; Cholesterol (Total cholesterol) in mmo/IL) 
c lati b orre on h I etween age, c o estero Mland I,B c D62P 
' 
Variables Correlation co-efficient p value Significance 
r 
Age r=0.373 p=O.OOO s 
BMI r=-0.150 p=0.15 NS 
Cholesterol r=0.285 p=0.007 s 
j Correlation between age, cholesterol, BMI and PAC-1 
Variables Correlation co-efficient p value Significance 
: r 
i 
I 
: A2e r= 0.586 p= 0.000 s 
j 
:l BMI r=-0.107 p=0.31 NS 
1'· 
Cholesterol r=0.375 p=O.OOO s 
1 
: DISCUSSION: 
To contribute in haemostasis, platelets ·need to be activated. However pathological 
activation .may result in pathological thrombosis. This pathological platelet activation has 
been noted in many clinical conditions like DVT, unstable angina and stroke. There are many 
· assays to monitor the status of the patients platelets, however they all measure different 
. things and therefore give a different picture of platelets. Physiologic assays in particular can 
' certainly show that platelet function has been inhibited but cannot effectively show that 
platelets have become activated. Also these are crude techniques which cannot detect the 
. subtle changes. Platelet count should be normal for these assays and these tests cannot be 
• performed in thrombocytopenic patients. Biochemical assays on the other hand can detect 
platelet activation long before they can be detected in physiologic assays. There are two 
principal assay system, ELISJ\ and. flow cyto~etry ~d ELISA has the advantage of being 
easy to perfonn and does not reqwre expensive equtpment. While on the other hand flow 
~ allows us to see, changes m individual platelets although flow cytometer is 
• probably the most accurate assay. The ease of .using ELISA makes the later most common 
assay system used. In flow cytometry another lDlportant though not a major factor is what 
antibodies are used from many available in the market. Different antibodies have different 
significance as e.g. P~C-1 .induction occurs with weak stimulation ~bile CD63 antigen 
requires very strong .snm~atton. On ~e ~ther han~ G~ 140 (P selectm , CD62P) does not 
preserve wen and ts unhkely to extst m the crrculatJ.on because ~it is cleared from the 
circulation by spleen. . 
In our study blood sam.pling was done by the investigator to avoid artifactual 
activation of platelets. Subjects with difficult or traumatic venepuncture were not included for 
further platelet activation studies. Tourniquet was not used for drawing blood and where 
necessary was used only for venepuncture. This was done since Rite he et. al. (2000b) in their 
1! 
study suggested effects of tourniquet pressure on plasma fibrinogen, platelet P-selectin, 
monocyte tissue factor and concluded that tourniquet pressure can be used· while drawing 
blood sample for these three heamostatic variables. However in their study they did not study 
the change in GPIIb/Illa with use of tourniquet. Due to these factors the use of tourniquet 
pressure was kept to the minimal. 
To meet with objective 1 of primary objectives, co-efficient of variation calculated for 
the study I for both CD62P and PAC-I; 5.2 and 3.8 % respectively showed that the technique 
was good and comparable with other studies. A relatively high CV for CD 62P was partially 
due to high variation in the percentage of this activation marker resulting from high 
1
• sensitivity of the technique. 
:. Later part of the study also showed that the platelet activation markers PAC-1 and CD 
62P were significantly higher in post menopausal women, as compared to the pre-
menopausal group. The levels of platelet activation markers in this study were compared with 
the control group since every study sample was run with control group sample to avoid over 
interpretation of results by faulty technique. The finding of increased platelet activation 
markers in post menopausal age group may correlate with the frequent thromboembolic 
events and may suggest a role of platelet activation in an increased incidence of 
cardiovascular disease in this population. Other studies have also shown an association 
between platelet activation or dysfunction and pulmonary embolism, deep vein thrombosis 
and disseminated intravascular coagulation. 
, ' Negative correlation was noted between estradiol and CD 62P in post-menopausal 
l women showing the beneficial effect of estradiol on platelets. Similarly PAC-I has negative 
i correlation in our study with estradiol. Other studies, which have shown the effect of 
: honnones on platelets, showed indirect evidence of beneficial effect of HR. T on platelets. 
: This is the first study, which showed the beneficial effect of estradiol on platelets determined 
': by activation dependent markers on flow cytometer. There was also positive correlation 
: observed between age and activation markers showing the effect of age on platelets and this 
might be explained by age related changes in vessel wall and its function. Serum cholesterol 
also showed positive correlation while there was no positive correlation between activation 
' markers and B:Ml. This might be explained due to difficulty in venepuncture in volunteers 
· with high BMI. The samples with difficult venepuncture were discarded and were not 
included in the study to avoid artifactual platelet activation. . 
When we studied our volunteers there was no clinical evidence of cardiovascular and 
thrombotic disease. However increase platelet activation was noted in post-menopausal 
women, this is why we can say there are other factors apart from the activation markers 
.. which results in clinical complications and out come in particular patient. However platelets 
play an important role in arterial thrombosis 
, Our study has several limitations~ of whichJuack-Of--measurement-of-platelet 
, function. Platelet function was not measured in our study due to lack of availability of 
, required facilities for such measurements. One limitation of the study is that we have not 
·looked into the reactivity of the platelet in both groups of population that is no in vitro 
stimulation was done. In other studies platelet reactivity was done with platelet activation 
markers. However these studies increase activation markers as determine in vivo technique. 
CONCLUSION: 
Results of this work demonstrated the effect of menopause on platelet activation 
markers. Following conclusions can be made from the results of our study. 
a) Determination of platelet activation markers by flow cytometer is a sensitive accurate 
technique. 
b) Platelet activation markers CD62P and PAC-1 were increased in post-menopausal women 
as compared to pre-menopausal women 
. b) With decrease in estradiol levels there is increase in activation markers in post-menopausal 
'I group. 
c) Also, there is increase in the activation markers with increase in serum cholesterol and 
j \ with increase in the age. 
I These results may suggest a role of platelets in increased incidence of thrombotic events and 
diseases in post-menopausal women. 
~, FUTURE RECOMMENDATIONS 
I Further studies are needed to be undertaken to investigate the effect of honnone replacement 
· , therapy in post-menopausal women on platelet activation markers. As we have shown in our 
study that there is negative correlation between estradiol level and CD62P and PAC-1. This 
can be achieved by double blinded cross over interventional study. Besides long term 
prospective looking at incidence of thrombotic events and platelet activation among post 
menopausal women. Such studies shall give more conclusive evidence about the possible 
effect of platelet activation markers. 
I CLINICAL IMPLICATIONS OF THE·STUDY: 
Demonstration of increased activation markers may provide valuable marker for 
evaluating patients with high risk for clinical complications and also to evaluate efficacy of 
anti-platelet drugs or effect of hormone replacement therapy in this susceptible group of 
population. · 
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Determination of Platelet Activation Markers in post and pre-menopausal women 
by Flow cytometer. 
(Presented in Malaysian Society of Hematology Meeting 2002, NCMS USM 2002 & 
ISEH) · (Best oral presentation and travel grant award) . 
Roshan TM., Normah J. Department of Hematology, School of Medical Sciences, 
University Sains Malaysia. 
Abstract 
Introduction. Pre-menopausal women have lower risk of cardiovascular disease compared 
to post menopausal women which is more age dependent in women than in men. 
Increased and disturbed platelet activation plays a major role in the pathophysiology of 
thrombosis and has been noted in different thrombotic disorders. Temporal association 
between cardiovascular disease and increased platelet activation is well established. The 
role of platelet activation needs to be evaluated in this population. 
Methods. Evaluation of Platelet activation markers was done in 49 post-menopausal 
(56.16 ± 0.83 years; mean± SEM) and 42 pre menopausal women (39.38years ± 1.09). 
Subjects were recnuted after informed verbal consent. The technique used for in vivo 
evaluation. of platelet Activation Markers by Flow cytometer using 3-color analysis 
(CD61 PerCP, CD62P and PACI) was previously developed and optimized. Blood· 
samples were drawn in a standardized manner to minimize in vitro activation of platelets. 
Samples were processed and analyzed in duplicate. 
Results. There was a significant increase in CD62P in post-menopausal women as 
compared to the control (pre-menopausal) group (7.28 ± 1.63 vs 0.8887 ± 0.1922; mean± 
SEM, p=O.OOI). Similarly PACI were significantly increased in post-menopausal group 
(29.45 ± 3.04 ·vs 5.22 ± 0.710; p<O.OOI). However there was no significant correlation 
between CD62P or PACl markers wit1Ls_ellll1L.1riglycerides,_:_estradiol-and-bod.Y-tnas~----
index in both groups. ·-
Conclusion. ~latelet Activation markers CD62P and PACI are increased in post-
menopausal women as compared to premenopausal women. These results may suggest a 
role in high incidence of cardiovascular disease in this group. 
Key words. Platelet activation markers, Post-menopausal women, Flow cytometry. 
Methodological development for in vivo determination of Platelet Activation 
Markers by Flow cytometry 
(P~esented in Malaysian Society of Hematology Meeting 2002) 
Roshan TM., Normah· J. Deparbnent of Hematology, School of Medical Sciences, 
University Sains Malaysia. 
Abstract 
Background: Platelet activation either disturbed and I or increased plays a major role in 
the pathophysiology of thrombosis. Different techniques show changes in platelet · 
reactivity but cannot establish its associa~~n with the particular condition. Some 
techniques on the other hand determine this association but cannot measure changes in 
plateJet reactivity and I or the extent of activation of individual platelets or detect distinct 
subpopUlation of platelets. Diagnostic value of the flow-cytometric .analysis of platelets 
activation in prothrotnbotic syndromes (diabetes, anti-phospholipid syndrome or 
secondary to drug induced platelet activation) is being established. Platelet aggregation 
studies are semi-quantitative and subject to standardization problems. Plasma separation 
is required for radioimmunoassays of plasma b-tbromboglobulin and platelet factor 4 
concentration are vulnerable to artifactual in vitro platelet activation. Soluble P-selectin 
in plasma may be of endothelial origin. Whole blood flow-cytometry assay has none of 
these limitations. Our aim was to develop and optimize the later technique. 
Methods: Blood was drawn using standardized technique to minilnize artifactual 
activation of platelets. And staining of platelets was performed within 10 .minutes of 
, sample collection. Sodium citrate (3.8%) was used as anticoagulant. Using butterfly 
cannulae (20 gauge) first 6mls of the sample was used for biochemical and hematological 
investigations and then 2mls were collected in a final dilution with anticoagulant of 1:9. 
' Use of tourniquet was kept 'minimal only for puncture, where n~cessary. Three colors 
1 analysis of platelet activation was perfoimed using CD61 PerCP, PAC-1 and CD{)2-P. 
Tests were p~rformed in duplicate. Data acquisition and analysis were done using Cell 
Quest software and Becton Dickson flow cytometer. 
Conclusion: Flow cytometery is a very sensitive and accurate technique for activation 
analysis of platelets and the use of this technique has good clinical implication. It has 
been shown to have high diagnostic sensitivity in ongoing tlu·ombogenesis in s~1bclinical 
progression of peripheral vascular disease. It does not have limitations seen by other 
techniques. 
